CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $262.91M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 9.89: safe zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.77BCNY262.91M · vs all stocks (USD)
Revenue (TTM)
127.35MCNY18.94M · vs all stocks (USD)
Profit Margin
-111.59%vs Biotechnology peers
Beta
0.2300xvs all stocks
52-Week Change
-55.23%vs all stocks
Market Capitalization
1.77BCNY262.91M · vs all stocks (USD)
Enterprise Value
1.46BCNY217.21M · vs all stocks (USD)
Price to Sales (TTM)
14.18xvs Biotechnology peers
Price to Book (MRQ)
2.35xvs Biotechnology peers
Enterprise to Revenue
11.47xvs Biotechnology peers
Enterprise to EBITDA
-19.33xvs Biotechnology peers
Gross Margin
25.21%vs Biotechnology peers
Profit Margin
-111.59%vs Biotechnology peers
Operating Margin
-59.85%vs Biotechnology peers
Return on Assets (TTM)
-6.86%vs Biotechnology peers
Return on Equity (TTM)
-20.00%vs Biotechnology peers
Revenue (TTM)
127.35MCNY18.94M · vs all stocks (USD)
Revenue per Share (TTM)
0.4640CNYUpdated Aug 21, 2026Quarterly Revenue Growth
-35.90%vs Biotechnology peers
Gross Profit (TTM)
22.66MCNY3.37M · vs all stocks (USD)
EBITDA (TTM)
-75.55MCNY-11.23M · vs all stocks (USD)
Net Income (TTM)
-142.12MCNY-21.13M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
113.97%vs Biotechnology peers
Operating Cash Flow (TTM)
3.36MCNY498.97K · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-11.70MCNY-1.74M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
-71.14MCNYFY2025 · Dec 31, 2025Revenue
141.93MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
97.22MCNYFY2025 · Dec 31, 2025Gross Profit
44.71MCNYFY2025 · Dec 31, 2025Operating Income
-78.24MCNY-11.64M · vs all stocks (USD)
Pre-tax Income
-132.75MCNYFY2025 · Dec 31, 2025Income Tax Expense
17.01MCNYFY2025 · Dec 31, 2025Net Income
-149.75MCNYFY2025 · Dec 31, 2025EBIT
-129.17MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-38.98MCNYFY2025 · Dec 31, 2025Research & Development
35.36MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
49.97MCNYFY2025 · Dec 31, 2025Other Operating Expenses
3.01MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
3.55MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
3.58MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.4989CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.4989CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
274.40MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
274.40MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-149.75MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
12.85MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
77.56MCNYFY2025 · Dec 31, 2025Free Cash Flow
2.32MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
296.37MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-149.75MCNYFY2025 · Dec 31, 2025Other Non-cash Items
3.62MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
178.32MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
45.37MCNYFY2025 · Dec 31, 2025Capital Expenditures
-75.24MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-75.24MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
10.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-219.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-2.71MCNYFY2025 · Dec 31, 2025Other Financing Charges
-21.52MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-233.23MCNYFY2025 · Dec 31, 2025Shares Outstanding
274.40MSharesUpdated Aug 21, 2026Float Shares
149.21MSharesUpdated Aug 21, 2026% Held by Insiders
48.27%vs all stocks
% Held by Institutions
1.11%vs all stocks
Total Cash (MRQ)
278.09MCNY41.35M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.02CNYUpdated Aug 21, 2026Total Debt (MRQ)
10.00MCNY1.49M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0144xvs Biotechnology peers
Current Ratio (MRQ)
4.23xvs Biotechnology peers
Book Value per Share (MRQ)
2.82CNYUpdated Aug 21, 2026Total Assets
809.47MCNY120.38M · vs all stocks (USD)
Total Current Assets
399.83MCNYFY2025 · Dec 31, 2025Total Liabilities
97.06MCNYFY2025 · Dec 31, 2025Total Non-current Assets
409.64MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
3.54MCNYFY2025 · Dec 31, 2025Total Current Liabilities
93.52MCNYFY2025 · Dec 31, 2025Cash
297.66MCNYFY2025 · Dec 31, 2025Cash Equivalents
3.86MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
301.52MCNYFY2025 · Dec 31, 2025Accounts Receivable
36.03MCNYFY2025 · Dec 31, 2025Inventory
35.88MCNYFY2025 · Dec 31, 2025Accounts Payable
27.23MCNYFY2025 · Dec 31, 2025Short-term Debt
10.03MCNYFY2025 · Dec 31, 2025Other Current Liabilities
10.64MCNYFY2025 · Dec 31, 2025Common Stock (Book)
274.40MCNYFY2025 · Dec 31, 2025Retained Earnings
-660.22MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
712.41MCNY105.94M · vs all stocks (USD)
Treasury Stock
26.14MCNYFY2025 · Dec 31, 202552-Week Low
5.47CNYUpdated Aug 21, 202652-Week High
16.98CNYUpdated Aug 21, 202652-Week Change
-55.23%vs all stocks
Beta
0.2300xvs all stocks
50-Day MA
6.61CNYUpdated Aug 21, 2026200-Day MA
8.02CNYUpdated Aug 21, 2026Avg 10-Day Volume
6.68MSharesUpdated Aug 21, 2026Avg 30-Day Volume
7.95MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-0.5200CNYUpdated Aug 21, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
Where is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 9.89: safe zoneNotable
Altman Z-Score: 9.89
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $262.91M, lower than 95% of all stocks globallySignificant
Market cap (USD): 262,909,554.663Global P5: 269,387,740.27
Revenue is $18.94M, lower than 95% of all stocks globallySignificant
Revenue (USD): 18,938,454.057Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
TriSalus Life Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Fischer Medical Ventures Ltd
Tier 1ProductionApproval-Gated PipelineFlowRule
Niagen Bioscience Inc.
Tier 1ProductionApproval-Gated PipelineRuleInterface
Ginwa Enterprise Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Senseonics Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRule
PharmaEngine, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Entrada Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
United Orthopedic Corporation
Tier 1ProductionApproval-Gated PipelineRule
Opus Genetics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Tiansheng Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Century Wind Power Co., Ltd.
2 interpretationsCash-Flow Ratios ElevatedUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Soulbrain Holdings Co., Ltd.
2 interpretationsCash-Flow Ratios ElevatedUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Hiecise Precision Equipment Co., Ltd.
2 interpretationsCash-Flow Ratios ElevatedUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated